Biología molecular del virus de la hepatitis C: Implicaciones para el desarrollo de nuevas terapias y de una vacuna profiláctica

Medicina Clinica

Volumn 116, Issue 5, 2001, Pages 191-197

  Forns, Xavier ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; HEPATITIS VACCINE; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ARTICLE; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; RECOMBINANT PROTEINS; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

EID: 0035835625     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(01)71766-6     Document Type: Conference Paper

References (46)

1. Rice CM. En: Fields BN, Knippe DM, Howley PM, editores. Fields virology. Filadelfia: Lippincot-Raven, 1996; 931-960.
2. Houghton M. En: Fields BN, Knippe DM, Howley PM, editores. Fields virology. Filadelfia: Lippnicot-Raven, 1996; 1035-1058.
3. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995; 15: 41-63.
4. McHutchinson JG, Stuart CG, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-1492.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alfa 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-1432.
6. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
7. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 1994; 343: 388-390.
8. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepaitis C virus. Trends Microbiol 2000; 7: 402-410.
9. Weirer AJ, Geysen HM. Christopherson C, Hall JE, Mason TJ, Saracco G et al. Evidence for immune selection of hepatitis C virus (HCV) putative glycoprotein variants: potential role in chronic HCV infections. Proc Natl Acad Sci USA 1992; 89: 3468-3471.
10. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci USA 1996; 93: 15394-15399.
11. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepalic inoculation with transcribed RNA Science 1997; 277: 570-574.
12. Yanagi M, Purcell RH, Emerson SU, Bukh. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the lives of a chimpanzee. Proc Natl Acad Sci USA 1997; 94: 8738-8743.
13. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV et al. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000; 97: 13318-13323.
14. Missale G, Bertoni R, Lamonaca V, Valli A, Massari M, Mori C et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cel-mediated immune response. J Clin Invest 1996; 98 706-714.
15. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmaz D, Weiner AJ et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: 580-587.
16. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110.
17. Gale MJ, Korth MJ, Tang NM, Tan SL, Hopkins DA, Dever TE et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230: 217-227.
18. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M et al. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci USA 1996; 93: 1759-1763.
19. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R et al. Binding of hepatitis C virus to CD81. Science 1998; 282: 938-941.
20. Dimmock MJ. Update on the neutralization of animal viruses. Rev Med Virol 1995; 5: 165-179.
21. Farci P, Aller HJ, Wong DC, Miller RH, Govindarajan S, Engle R et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994; 91: 7792-7797.
22. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995; 345: 1173-1174.
23. Krawczynski F, Fattom A, Culver D, Kamili S, Spelbring J, Basham L et al. Passive transfer of anti-HCV in chronic and acute HCV infection in chimpanzees - trials of experimental immune treatment. Hepatology 1999; 30: A423.
24. Feray C, Gigou M, Samue D, Ducot B, Maisonneuve P, Reynes M et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 1998; 128: 810-816.
25. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C virus infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-1611
26. Wong DK, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L et al. Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. J Immunol 1998; 160: 1479-1488.
27. Takaki A, Wiese M, Maertens G, Depal E, Seifert U, Liebetrau A et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
28. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10: 439-449.
29. Thimme R, Bukh J, Chang KM, Pemberten J, Purcell RH, Chisari FV. HCV persists despite a multispecific peripheral and intrahepatic T cell response in acutely infected chimpanzees. Hepatology 1999; 30: A422.
30. Bechmann M, Liang TL. Vaccine development for hepatitis C. Sem Liver Dis 2000; 20: 211-226.
31. Choo QL, Kuo G, Ralston R, Weiner A, Chen D, Van Nest G et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994; 91: 1294-1298.
32. Houghton M, Choo QL, Chien D, Kuo G, Weiner A, Coates S et al. Development of an HCV vaccine. En: Rizzetto M, Purcell RH, Gerin JL, Verme G, editores. Viral hepatitis and liver diseases. Turin: Minerva Medica, 1997; 656-659.
33. Tighe H, Corr M, Reman M, Raz E. Gene vaccination: plasmic DNA is more than just a blueprint. Immunol Today 1998; 19: 89-97.
34. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNA immunization of mice and macaoues with plasmids encoding hepatitis C virus envelope E2 protein expressed intracellularly and on the cell surface. Vaccine 1999; 17: 1992-2002.
35. Fournillier A, Depla E, Karayiannis P, Vidalin O, Maertens G, Trepo C et al. Expression of noncovalent hepatitis C virus envelope E1-E2 complexes is not required for the induction of antibodies with neutraliziong properties following DNA immunization. J Virol 1999; 73: 7497-7504.
36. Brinster C, Inchauspe G. DNA vaccines for hepatitis C virus. Intervirology 2001. En prensa.
37. Forns X, Allander I, Rchwer-Nutter P, Bukh J. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface. Virology 2000; 274: 75-85.
38. Forns X, Payette P, Ma X, Satterfield W, Eder G, Mushahwar IK et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology 2000; 32: 618-625.
39. Encke J, Zu Pullitz J, Geissler M, Wands JR. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998; 161: 4917-4923.
40. Lee SW, Sung YC. Optimal induction of hepatitis envelope-specific immunity by bicistronic plasmid DNA inoculation with granulocyte-macrophage colony-stimulating factore gene. J Virol 1998; 72: 8430-8436.
41. Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellular and humoral immune responses to hepatitis C virus protein using DNA-based vaccines augmented with cytokine-expressing plasmids. J Immunol 1997; 158: 1231-1237.
42. Makimura M, Miyake S, Akino N, Takamori K, Matsuura Y, Miyama T et al. Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus. Vaccine 1996; 14: 28-36.
43. Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J. Highly attenuated poxvirus vectors. NYVAC, ALVAC, and TROVAC. Dec Biol Stand 1995; 84: 159-163.
44. Moss B, Carroll MW, Wyatt LS, Bennink JR, Mirsch VM, Goldstein S et al. Host range restricted, non-replicating vaccinina virus vectors as vaccine candidates. Adv Exp Med Biol 1996; 397: 7-13.
45. Esumi M, Rikihisa T, Nishimura S, Goto J, Mizuno K, Zhou YH et al. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis c virus in chimpanzees. Arch Virol 1999; 144: 973-980.
46. Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM. Recent advances with recombinant bacterial vaccine vectors. Mol Med Today 2000; 6: 66-71.